Khiron Life Sciences (CVE:KHRN) to Commence Extraction

James West
|

Khiron Life Sciences Corp (CVE:KHRN) (OTCMKTS:KHRNF) (FRA:4KH) joined the ranks of GMP certified cannabis extractors in the first week of June with the announcement of their state-of-the-art, 14,000 square foot ISO 17025-compliant extraction and analysis lab. This in addition to Khiron’s planned 80,00 square foot greenhouse expansion bringing the company’s producing footprint to over 100,000 square feet. As, well, Khiron has established distribution networks to supply high quality medical cannabis produced in Khiron’s main facility, with signed agreements with 903 pharmacies across Colombia and Khiron Clinics.

For more information and most recent images from the Company’s cultivation, extraction analysis facilities, please visit https://investors.khiron.ca/gallery

Khiron is often described as the leading Latin American cannabis player, with a management team and Board of Directors that makes it very clear the company is intent on using low-cost Colombian extract to vault into a leading position in medical cannabis, cosmeceuticals, and bioceutical categories.

Vicente Fox, the former president of Mexico, is now a director and spokesperson for the company. “Khiron Life Sciences is the leading cannabis company operating in Latin America,” he said during a recent interview on Midas Letter LIVE. “Mexico’s economy is the most open economy in the world. We trade with 42 different economies. We have [Free] Trade Agreements. The most important one of them is North America. The trade agreement with Canada, United States and Mexico, which has the largest trade balance in the world, approaching a trillion U.S Dollars a year. So every year we trade a very large sum between the three economies,” he said.

Extraction of cannabinoids from Cannabis and Hemp are widely anticipated to be much bigger than premium dried flower in terms as a share of global cannabis consumption. According to Deloitte’s recent research report, the market for edibles and other consumable cannabis products will reach $2.5 billion a year in Canada alone. Edibles are almost entirely manufactured using extracted cannabis oils, since they blend well with other typical food ingredients once rendered water soluble.

For those who don’t know, food, beverages, edibles, topical creams, pet products and tinctures make up the much bally-hooed “Consumer Packaged Goods” category that has become almost a cliché in cannabis company presentation decks. Many are those who aspire to the holy grail of cannabis market share, but few are as well positioned in Latin America as Khiron.

Much of Latin America – including Colombia, Peru, Chile and Brazil – are currently not planning to permit recreational products in their markets, meaning that extracts will be the ingredients for primarily medical, supplements and pet products in the context of legal products.

Though likely to change at some point in the future, Latin America remains, for the most part, a medical market. Except, of course, for ‘cosmeceuticals’.

Khiron Brand Kuida Poised to Dominate

Gwyneth Paltrow is possibly the best-known celebrity to embrace the idea that cannabinoids in beauty products might become “a thing”. Her line – Goop – has already exploited the insatiable mania surrounding all things CBD by announced a partnership with cannabis dispensary chain MedMen to endorse a line of marijuana products last year.

Celebrities from Melissa Etheridge to Snoop Dog to Seth Rogen are all cashing in on the cannabis craze by lending their names to cannabis-forward brands, even ahead of legislation that would permit such ingredients in products.

In that respect, Latin America may actually be leading the race to put CBD-infused skin care products into the hands of consumers with its Kuida line of beauty and wellness products.

According to Khiron’s Director of Skin Care Elsa Navarro, “we have a population of nearly 40 million inhabitants here in Colombia. We have a big opportunity, a big market, but we’re not only considering right now Colombia as our backyard; we’re considering Latin America, and we’re considering a worldwide population. You know, the industry is considered to be $130 billion dollar, so it’s a big opportunity for us, not only in Colombia, but in the world.”

While brands like Paltrow’s Goop will obviously get all the attention in the United States, the effect of so much celebrity firepower coming into the space will have the effect of burnishing the appeal of all products out there in the world of cannabis cosmetics, and Khiron will be the beneficiary of that.

WATCH: Khiron Skin Care Director Elsa Navarro on Kuida

 

**IMPORTANT! BY VIEWING OUR CONTENT YOU EXPLICITLY AGREE TO THE FOLLOWING. PLEASE READ CAREFULLY**

Notice for Forward-Looking Information

Certain statements in this press release are forward-looking statements and are prospective in nature. Forward-looking statements are not based on historical facts, but rather on current expectations and projections about future events, and are therefore subject to risks and uncertainties which could cause actual results to differ materially from the future results expressed or implied by the forward-looking statements. Such forward-looking information includes that Khiron Life Sciences Corp will be a big, successful company in the cannabis sector; that cannabis use and sales will grow and KHIRON’s sales along with it; KHIRON’s intended acquisition of various foreign companies and expansion into the European and South and North American markets; that cosmeceuticals is and will continue to be a fast growing and profitable sector of the cannabis industry; and that it will be able to carry out its business plans.

 

Readers are cautioned to not place undue reliance on forward-looking information. Forward looking information is subject to a number of risks and uncertainties that may cause actual results or events to differ materially from those contemplated in the forward-looking information, and even if such actual results or events are realized or substantially realized, there can be no assurance that they will have the expected consequences to, or effects on KHIRON. Such risks and uncertainties include, among other things: that a regulatory approval that may be required for the intended acquisitions and subsequent sales are not obtained or are obtained subject to conditions that are not anticipated; growing competition for intended acquisitions in the cannabis industry; potential future competition in the markets KHIRON operates for sales; competitors may quickly enter the industry; general economic conditions in the US, Canada and globally; the inability to secure financing necessary to carry out its business plans; competition for, among other things, capital and skilled personnel; the possibility that government policies or laws may not permit legal cannabis sales or growth or that favorable laws in place may change; KHIRON not adequately protecting its intellectual property; interruption or failure of information technology systems; the cannabis market may not grow as expected; KHIRON’s technology may not achieve the expected results and its accomplishments may be limited; even if it is granted patents, it may not have success at licensing its technologies or sell its products at the rate expected; planned acquisitions and partnerships may not materialize because of inability to agree on terms with prospective partners or targets; KHIRON’s business plan also carries risk, including its ability to comply with all applicable governmental regulations in a highly regulated business; incubator risk investing in target companies or projects which have limited or no operating history and are engaged in activities currently considered illegal under US federal and foreign laws; and other regulatory risks relating to KHIRON’s business, financings and strategic acquisitions, including securities laws, trade rules, and foreign country regulation that is not the same as Canadian or US regulations.

 

DISCLAIMERS

PAID ADVERTISEMENT. This communication is a paid advertisement and is not a recommendation to buy or sell securities. James West, Global Financial Network Ltd. and Midas Letter Media Corp. and their owners, managers, employees, and assigns (collectively “the Company”) has been paid by the profiled company or a third party to disseminate this communication. In this case the Company has been paid by KHIRON $100,000 per month for one year as of May 15, 2019 for a newsletter campaign and certain banner ads, of which a portion is spent to produce multi-media content and a portion to the advertising budget targeting investor. In addition, the Company owns 150,000 Restricted Share Units (RSU’s) of KHIRON, and will benefit from its price appreciation. This compensation and our rights ownership in KHIRON is a major conflict with our ability to be unbiased, more specifically:

This communication is for entertainment purposes only. Never invest purely based on our communication. Gains mentioned in our newsletter and on our website may be based on end-of- day or intraday data. We have been compensated by KHIRON to conduct investor awareness advertising and marketing for KHIRON. Therefore, this communication should be viewed as a commercial advertisement only. We have not investigated the background of the profiled company. The profiled company or its affiliates may liquidate shares of the profiled company at or near the time you receive this communication, which has the potential to hurt share prices. Frequently companies profiled in our newsletters experience a large increase in volume and share price during the course of investor awareness marketing, which often end as soon as the investor awareness marketing ceases. The investor awareness marketing may be as brief as one day, after which a large decrease in volume and share price is likely to occur.

We do not guarantee the timeliness, accuracy, or completeness of the information on our site or in our newsletters. The information in our communications and on our website is believed to be accurate and correct, but has not been independently verified and is not guaranteed to be correct. The information is collected from public and non-public sources but is not researched or verified in any way whatsoever to ensure the information is correct.

SHARE OWNERSHIP. The Company, which includes the owner and publisher of the Midas Letter owns Restricted Share Units of this featured company and therefore has an additional incentive to see the featured company’s stock perform well. The Company will not notify the market when it decides to buy or sell shares of this profiled company in the market. The Company may be buying and selling additional shares of the featured company for its own profit. This is why we stress that you conduct extensive due diligence as well as seek the advice of your financial advisor or a registered broker-dealer before investing in any securities.

NOT AN INVESTMENT ADVISOR. The Company and its affiliates are not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. ALWAYS DO YOUR OWN RESEARCH and consult with a licensed investment professional before making an investment. This communication should not be used as a basis for making any investment.

INDEMNIFICATION/RELEASE OF LIABILITY. By reading this communication, you agree to the terms of this disclaimer, including, but not limited to: releasing the Company, its affiliates, assigns and successors from any and all liability, damages, and injury from the information contained in this communication. You further warrant that you are solely responsible for any financial outcome that may come from your investment decisions.

RISK OF INVESTING. Investing is inherently risky. While a potential for rewards exists, by investing, you are putting yourself at risk. You must be aware of the risks and be willing to accept them in order to invest in any type of security. Don’t trade with money you can’t afford to lose. This is neither a solicitation nor an offer to Buy/Sell securities.

James West

James West

Editor and Publisher

I employ a Capital Efficiency Model that dictates money should never be exposed for longer than is absolutely necessary to the possibility of being lost. Thus, I routinely sell half my position when a stock doubles from my entry price, and I sell stocks that lose 20%, unless there are...
More Info...

[email protected] | |

Midas Letter is provided as a source of information only, and is in no way to be construed as investment advice. James West, the author and publisher of the Midas Letter, is not authorized to provide investor advice, and provides this information only to readers who are interested in knowing what he is investing in and how he reaches such decisions.

Investing in emerging public companies involves a high degree of risk and investors in such companies could lose all their money. Always consult a duly accredited investment professional in your jurisdiction prior to making any investment decision.

Midas Letter occasionally accepts fees for advertising and sponsorship from public companies featured on this site. James West and/or Midas Letter may also receive compensation from companies affiliated with companies featured on this site. James West and/or Midas Letter also invests in companies on this site and so readers should view all information on this site as biased.

Free Newsletter,
Priceless Content.

Be the first to hear from Midas Letter on all things Cannabis.